Altimmune Stock Price, News & Analysis

Altimmune (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, has announced its upcoming participation in the Citizens Life Sciences Conference. The company's management team will engage in a fireside chat scheduled for Wednesday, May 7, 2025, at 9:30 a.m. EDT.

Interested parties can access the session through a webcast available in the Events section of the Altimmune website. This participation demonstrates the company's continued engagement with the investment community and commitment to transparency in communications.

Altimmune (Nasdaq: ALT) has announced a virtual R&D Day scheduled for March 13, 2025 at 12:00 pm Eastern Time. The event will showcase presentations from Key Opinion Leaders (KOLs) focusing on multiple therapeutic areas for pemvidutide:

• Obesity treatment applications
• MASH (Metabolic Dysfunction-Associated Steatohepatitis)
• Two additional newly FDA-cleared indications

The R&D Day will cover the scientific basis for pemvidutide across these indications, review existing clinical data, and outline development strategies. A significant highlight will be discussing the upcoming topline data from the IMPACT Phase 2b trial in MASH, expected in Q2 2025. The event will be accessible through https://investorday.altimmune.com and the company's website Events section.

Altimmune (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, has announced its upcoming participation in the Leerink Global Healthcare Conference in March 2025. The company's management team will engage in a fireside chat session during the conference.

The event will be accessible via webcast through the Events section of the Altimmune website, providing investors and interested parties an opportunity to follow the discussion remotely.

Altimmune (NASDAQ: ALT) has announced its Q4 and full year 2024 financial results, highlighting significant progress in its pemvidutide development program. The company reports cash reserves of $131.9 million as of December 31, 2024.

Key developments include:

• Top-line data from Phase 2b IMPACT trial in MASH expected in Q2 2025
• FDA clearance received for two additional pemvidutide indications
• Phase 2 trials for new indications to commence mid-2025

Financial highlights for Q4 2024:

• R&D expenses: $19.8 million
• G&A expenses: $5.1 million
• Net loss: $23.2 million ($0.33 per share)

The company strengthened its Board with two pharmaceutical industry veterans and plans to hold a virtual R&D Day on March 13, 2025.

Altimmune (Nasdaq: ALT) has appointed Teri Lawver and Jerry Durso to its Board of Directors as the company advances into late-stage clinical development for pemvidutide and prepares for transition to a pre-commercial organization.

Lawver brings nearly 30 years of healthcare experience, most recently serving as Chief Commercial Officer at Dexcom where she led the launch of the industry's first over-the-counter glucose biosensor. Previously, she spent 20 years at Johnson & Johnson in senior leadership roles, including global commercial responsibility for Janssen's $16 billion immunology portfolio.

Durso has over 30 years of leadership experience, most recently as CEO of Intercept Pharmaceuticals where he built a successful rare liver disease franchise and led the company through its acquisition by Alfasigma. He previously spent over 20 years at Sanofi in various senior positions.

Both executives will help guide Altimmune's strategic vision to develop and commercialize pemvidutide, which has shown promising effects on liver defatting, weight loss, and serum lipid improvements.

Altimmune (Nasdaq: ALT) has announced it will release its fourth quarter and full year 2024 financial results on Thursday, February 27, 2025. The clinical-stage biopharmaceutical company will host a conference call at 8:30 am E.T. on the same day, during which management will discuss financial results and provide a business update.

The conference call will be accessible through a webcast on Altimmune's Investor Relations website. Interested participants can register online to receive dial-in numbers and a unique PIN for call access. A replay of the call will be available on the company's Investor Relations website for up to three months following the event.

Altimmune (Nasdaq: ALT), a clinical-stage biopharmaceutical company, has announced its upcoming participation in the Guggenheim SMID Cap Biotech Conference. The company's management team will engage in a fireside chat scheduled for Wednesday, February 5, 2025, at 9:30 a.m. EST.

Interested parties can access the session through a webcast available in the Events section of the Altimmune website. This participation represents an opportunity for investors and stakeholders to gain insights into the company's developments and strategic direction.

Altimmune (Nasdaq: ALT) announced its addition to the Nasdaq Biotechnology Index (NBI) effective December 23, 2024. The company's CEO, Vipin K. Garg, highlighted this as an important recognition following a year of major progress. Looking ahead to 2025, the company anticipates significant milestones, including topline data from the Phase 2b IMPACT trial of pemvidutide in MASH expected in Q2. The NBI, established in 1993, tracks Nasdaq-listed biotechnology and pharmaceutical securities that meet specific eligibility criteria including market capitalization, trading volume, and seasoning requirements.

Altimmune (Nasdaq: ALT) announced that their Chief Medical Officer, Dr. Scott Harris, will present at the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders in Washington, D.C. The presentation will focus on body composition data from the Phase 2 MOMENTUM trial of pemvidutide in obesity treatment. Dr. Harris will participate in a panel discussion titled 'Muscle Wasting in Weight Loss Therapy' during the session 'Treatment Approaches to Address Muscle Wasting in the Context of Obesity Therapy & Regulatory Issues' on Friday, December 6, 2024, at 9:30 am ET.